Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.

Yale JF, Catarig AM, Grau K, Harris S, Klimek-Abercrombie A, Rabasa-Lhoret R, Reardon L, Woo V, Liutkus J

Diabetes, obesity & metabolism15 Aug 2021Cited by 34 (Europe PMC)

PMID34142429PMCIDPMC9291287DOI10.1111/dom.14468PepBankPUB-34142429

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, once-weekly semaglutide lowered mean HbA1c by 0.9 percentage points.
In plain wordsIn adults with type 2 diabetes in routine care, once-weekly semaglutide was linked to lower HbA1c, about 0.9 percentage points.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to end of study
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
HbA1c reduction
0.9 %-point
end of study
Source sentences
Summary
Mean HbA1c was reduced by 0.9%-point (95% confidence interval [CI]: 0.97; 0.78).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks).
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242901
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, once-weekly semaglutide lowered mean body weight by 4.3 kg.
In plain wordsIn adults with type 2 diabetes in routine care, once-weekly semaglutide was linked to a weight loss of about 4.3 kg.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Body weight reduction
4.3 kg
end of study
Source sentences
Summary
Mean BW was reduced by 4.3 kg (95% CI: 4.79; 3.76).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included change in body weight (BW), waist circumference and patient-reported outcomes (PROs) and the proportion of patients achieving HbA1c of less than 7.0%, weight loss (WL) of 5% or higher, and a composite of HbA1c reduction of 1% or higher and WL of 3% or higher at EOS.
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242902
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, 46.9% reached HbA1c below 7.0% at end of study, up from 19.0% at baseline.
In plain wordsIn adults with type 2 diabetes in routine care, 46.9% reached an HbA1c below 7.0% on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with HbA1c below 7.0%
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.0%
46.9%
end of study
Source sentences
Summary
At EOS, 46.9% of patients achieved HbA1c of less than 7.0%
2 context sentences(design, population, supporting numbers)
Summary · context
86 (19.0%) patients had HbA1c of less than 7.0%.
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242903
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, 40.9% achieved weight loss of 5% or higher at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, 40.9% lost at least 5% of body weight on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with weight loss of 5% or higher
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion with WL >=5%
40.9%
end of study
Source sentences
Summary
At EOS, 46.9% of patients achieved HbA1c of less than 7.0%, 40.9% achieved WL of 5% or higher and 24.1% achieved the composite endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242904
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, 24.1% achieved the composite of HbA1c reduction of at least 1% and weight loss of at least 3%.
In plain wordsIn adults with type 2 diabetes in routine care, 24.1% reached both a clear HbA1c drop and some weight loss on semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with composite endpoint (HbA1c reduction of 1% or more and weight loss of 3% or more)
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion with composite endpoint
24.1%
end of study
Source sentences
Summary
At EOS, 46.9% of patients achieved HbA1c of less than 7.0%, 40.9% achieved WL of 5% or higher and 24.1% achieved the composite endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included change in body weight (BW), waist circumference and patient-reported outcomes (PROs) and the proportion of patients achieving HbA1c of less than 7.0%, weight loss (WL) of 5% or higher, and a composite of HbA1c reduction of 1% or higher and WL of 3% or higher at EOS.
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242905
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, patient-reported outcomes improved from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, patient-reported outcomes improved over about 30 weeks of once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreasePatient-reported outcomes
Study
n: not reported in source
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
PROs improved from baseline to EOS.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242906
07HumanObservational studySafety outcome
In adults with type 2 diabetes in routine care, no new safety concerns were reported for once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, no new safety concerns were reported with once-weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableSafety
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
No new safety concerns were reported.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled.
Report a problemFND-3414242907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT03457012

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Novo Nordisk A/Sn = 46229 Mar 2018 to 19 Dec 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Sept 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.